Highlights
An individual patient data (IPD) meta-analysis of six randomized phase 3 trials, encompassing 6,057 patients, found that adding hormone therapy to postoperative radiotherapy (PORT) did not significantly improve overall survival (HR 0.87, p=0.06).
Pre-radiotherapy PSA levels were identified as a critical predictive biomarker; patients with a PSA of 0.5 ng/mL or less derived no meaningful survival benefit from either short-term or long-term hormone therapy.
